Fry D - Search Results

1

Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.

Ma Y, Li J, Wang H, Chiu Y, Kingsley CV, Fry D, Delaney SN, Wei SC, Zhang J, Maitra A, Yee C. Ma Y, et al. Among authors: fry d. Gastroenterology. 2020 Jul;159(1):306-319.e12. doi: 10.1053/j.gastro.2020.03.018. Epub 2020 Mar 14. Gastroenterology. 2020. PMID: 32179091 Free PMC article.

2

Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.

Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HD, Winters RT, Denny WA. Rewcastle GW, et al. Among authors: fry dw. J Med Chem. 1998 Feb 26;41(5):742-51. doi: 10.1021/jm970641d. J Med Chem. 1998. PMID: 9513602

3

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer.

Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW. Allen LF, et al. Semin Oncol. 2002 Jun;29(3 Suppl 11):11-21. doi: 10.1053/sonc.2002.34049. Semin Oncol. 2002. PMID: 12138393 Review.

4

Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.

Klutchko SR, Zhou H, Winters RT, Tran TP, Bridges AJ, Althaus IW, Amato DM, Elliott WL, Ellis PA, Meade MA, Roberts BJ, Fry DW, Gonzales AJ, Harvey PJ, Nelson JM, Sherwood V, Han HK, Pace G, Smaill JB, Denny WA, Showalter HD. Klutchko SR, et al. Among authors: fry dw. J Med Chem. 2006 Feb 23;49(4):1475-85. doi: 10.1021/jm050936o. J Med Chem. 2006. PMID: 16480284

5

Tyrosine kinase inhibitors. 3. Structure-activity relationships for inhibition of protein tyrosine kinases by nuclear-substituted derivatives of 2,2'-dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide).

Rewcastle GW, Palmer BD, Dobrusin EM, Fry DW, Kraker AJ, Denny WA. Rewcastle GW, et al. Among authors: fry dw. J Med Chem. 1994 Jun 24;37(13):2033-42. doi: 10.1021/jm00039a016. J Med Chem. 1994. PMID: 8027985

6

Tyrosine kinase inhibitors. 1. Structure-activity relationships for inhibition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihydro-2-thioxo-1H-indole-3-alkanoic acids and 2,2'-dithiobis(1H-indole-3-alkanoic acids).

Thompson AM, Rewcastle GW, Tercel M, Dobrusin EM, Fry DW, Kraker AJ, Denny WA. Thompson AM, et al. Among authors: fry dw. J Med Chem. 1993 Aug 20;36(17):2459-69. doi: 10.1021/jm00069a003. J Med Chem. 1993. PMID: 8355247

7

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.

Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, Showalter HD, Fry DW, Kraker AJ, Denny WA. Bridges AJ, et al. Among authors: fry dw. J Med Chem. 1996 Jan 5;39(1):267-76. doi: 10.1021/jm9503613. J Med Chem. 1996. PMID: 8568816

8

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.

Rewcastle GW, Palmer BD, Thompson AM, Bridges AJ, Cody DR, Zhou H, Fry DW, McMichael A, Denny WA. Rewcastle GW, et al. Among authors: fry dw. J Med Chem. 1996 Apr 26;39(9):1823-35. doi: 10.1021/jm9508651. J Med Chem. 1996. PMID: 8627606

9

Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.

Rewcastle GW, Palmer BD, Bridges AJ, Showalter HD, Sun L, Nelson J, McMichael A, Kraker AJ, Fry DW, Denny WA. Rewcastle GW, et al. Among authors: fry dw. J Med Chem. 1996 Feb 16;39(4):918-28. doi: 10.1021/jm950692f. J Med Chem. 1996. PMID: 8632415

10

Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro.

Denny WA, Rewcastle GW, Bridges AJ, Fry DW, Kraker AJ. Denny WA, et al. Among authors: fry dw. Clin Exp Pharmacol Physiol. 1996 May;23(5):424-7. doi: 10.1111/j.1440-1681.1996.tb02752.x. Clin Exp Pharmacol Physiol. 1996. PMID: 8713682

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

887 results

Search Page

Filters